Edgewise Therapeutics (EWTX)
Developer of sarcomere modulators for hypertrophic cardiomyopathy and heart failure.
$41.26
vs last close−3.25 (−7.31%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 110.32% | 119.82M shares | |
|---|---|---|---|
| 238 holders · as of Jun 30, 2026 | |||
| Insiders | 0.26% | 279.6K shares | |
| 9 holders · as of Aug 14, 2026 | |||
| Strategic holders | 5.45% | 5.92M shares | |
| 1 holder · as of May 15, 2026 | |||
| Adds to | 116.03% | ||
108.60M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 116.03%; nothing is left for Other.
13F, as of Jun 30, 2026
238 holders · 119.82M shares · 45 new positions · 128 increased · 75 reduced · 30 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Orbimed Advisors LLC | 15.52M | 14.29% | 0 | Aug 14, 2026 |
| Paradigm Biocapital Advisors LP | 10.22M | 9.41% | +2.85M | Aug 14, 2026 |
| Ra Capital Management, L.P. | 8.39M | 7.73% | −2.04M | Aug 14, 2026 |
| BlackRock, Inc. | 6.61M | 6.08% | +133.3K | Aug 7, 2026 |
| Jupiter Topco LLC | 6.08M | 5.59% | +6.08Mnew | Aug 14, 2026 |
| FMR LLC | 5.49M | 5.05% | +4.47M | Aug 13, 2026 |
| Novo Holdings A/S | 5.35M | 4.93% | 0 | Aug 14, 2026 |
| Driehaus Capital Management LLC | 4.73M | 4.35% | +250.7K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Orbimed Advisors LLCincl. Orbimed Capital LLC, Orbimed Capital GP Vi LLC +1 more | 14.50% | 15.25M | 13D | May 12, 2025 |
| RA Capital Management, L.P. | 9.90% | 10.43M | 13G | Nov 14, 2025 |
| Baker Bros. Advisors LP | 6.90% | 7.31M | 13G | Aug 14, 2025 |
| Paradigm BioCapital Advisors LP | 6.20% | 6.54M | 13G | Feb 17, 2026 |
| Janus Henderson Group PLC | 5.50% | 5.92M | 13G | May 15, 2026 |
| BlackRock, Inc. | 5.50% | 5.82M | 13G | Jul 17, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 12, 2026 | Kevin Kochdirector, officer: President and CEO | Sale · 3 lots | 17,971 | $43.68 | 52,488 |
| Aug 12, 2026 | Behrad Derakhshanofficer: Chief Business Officer | Sale · 4 lots | 5,100 | $43.81 | 31,826 |
| Aug 12, 2026 | John R. Mooreofficer: General Counsel | Sale · 4 lots | 5,016 | $43.82 | 17,697 |
| Aug 12, 2026 | Alan J. Russelldirector, officer: Chief Scientific Officer | Sale · 3 lots | 5,901 | $43.73 | 31,466 |
| Aug 13, 2026 | Joanne M. Donovanofficer: CMO | Sale | 2,919 | $43.41 | 8,625 |
| Aug 12, 2026 | Joanne M. Donovanofficer: CMO | Sale · 4 lots | 6,522 | $43.85 | 11,544 |
| Jul 1, 2026 | Alan J. Russelldirector, officer: Chief Scientific Officer | Sale · 2 lots | 200,000 | $39.41 | 24,555 |
| May 4, 2026 | Joanne M. Donovanofficer: CMO | Sale | 5,230 | $31.29 | 4,367 |
| May 5, 2026 | Joanne M. Donovanofficer: CMO | Sale | 50,000 | $38.57 | 4,367 |
| Apr 1, 2026 | Joanne M. Donovanofficer: CMO | Sale | 28,662 | $32.31 | 9,597 |
House and Senate disclosures
Not reported.